Evidence map›Paper›PMID 11714747›Full record

ArticleThe Journal of experimental medicine2001

Determinants of viral clearance and persistence during acute hepatitis C virus infection.

R Thimme, D Oldach, K M Chang, C Steiger, S C Ray, F V Chisari

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 466 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
466citing papers in PubMed, 1 pooled it
28.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

466 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,176 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Peripheral PD-1Frontiers in immunology · 2019
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Biomarkers in Detection of Hepatitis C Virus Infection.Pathogens (Basel, Switzerland) · 2024
    Review
  19. Review
  20. Article

406 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

R ThimmeDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA.
D Oldach
K M Chang
C Steiger
S C Ray
F V Chisari
Scripps Research Institute · USJohns Hopkins University · USUniversity of Maryland, Baltimore · US

Funding

VPA 985 IN LIVER CIRRHOSIS &ASCITESM01RR000833 · NCRR · SCRIPPS RESEARCH INSTITUTE · PI ZURAW, BRUCE L. · 1985 to 2004
$14.0M
PATHOGENESIS OF LIVER DISEASE IN HEPATITISR01AI020001 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CHISARI, FRANCIS VINCENT · 1985 to 2012
$7.4M
CELLULAR IMMUNITY--OUTCOME HEPATITIS C VIRUS INFECTIONR01AI047519 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 1999 to 2010
$3.1M
NEEDLESTICK HCV EXPOSURE: VIROLOGIC &IMMUNOLOGIC EVENTSR01AI047364 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI OLDACH, DAVID W · 1999 to 2003
$1.9M
SEQUENCE SELECTION AND PERSISTENCE OF HEPATITIS CR01DK057998 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI RAY, STUART C · 1999 to 2003
$1.1M
NCRR NIH HHS M01 RR000833NCRR NIH HHS RR 00833NIAAA NIH HHS AA 12859NIAID NIH HHS AI 20001NIAID NIH HHS AI-47364NIAID NIH HHS AI 47519NIAID NIH HHS R01 AI020001NIAID NIH HHS R01 AI047364NIAID NIH HHS R01 AI047519NIDDK NIH HHS DK 57998NIDDK NIH HHS R01 DK057998
6 · The paper itself

Abstract

The virological and immunological features of hepatitis C virus (HCV) infection were studied weekly for 6 months after accidental needlestick exposure in five health care workers, four of whom developed acute hepatitis that progressed to chronicity while one subject cleared the virus. In all subjects, viremia was first detectable within 1-2 weeks of inoculation, 1 month or more before the appearance of virus-specific T cells. The subject who cleared the virus experienced a prolonged episode of acute hepatitis that coincided with a CD38+ IFN-gamma- CD8+ T cell response to HCV and a small reduction in viremia. Subsequently, a strong CD4+ T cell response emerged and the CD8+ T cells became CD38- and started producing IFN-gamma in response to HCV, coinciding with a rapid 100,000-fold decrease in viremia that occurred without a corresponding surge of disease activity. Chronic infection developed in two subjects who failed to produce a significant T cell response and in two other subjects who initially mounted strong CD4+ T cell responses that ultimately waned. In all subjects, viremia was higher at the peak of acute hepatitis than it was when the disease began, and the disease improved during the viremia. These results provide the first insight into the host-virus relationship in humans during the incubation phase of acute HCV infection, and they provide the only insight to date into the virological and immunological characteristics of clinically asymptomatic acute HCV infection, the commonest manifestation of this disease. In addition, the results suggest that the vigor and quality of the antiviral T cell response determines the outcome of acute HCV infection, that the ability of HCV to outpace the T cell response may contribute to its tendency to persist; that the onset of hepatitis coincides with the onset of the CD8+ T cell response, that disease pathogenesis and viral clearance are mediated by different CD8+ T cell populations that control HCV by both cytolytic and noncytolytic mechanisms, and that there are different pathways to viral persistence in asymptomatic and symptomatic acute HCV infection.

Indexed as

Acute DiseaseAdultAlanine TransaminaseCD4-Positive T-LymphocytesFemaleHepatitis CHumansInterferon-gammaMaleMiddle AgedRNA, ViralAlanine TransaminaseInterferon-gammaRNA, Viral

Identifiers

PMID11714747
PMCPMC2193681
OpenAlexW2130259551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.